CN112094336A - 一种Avexitide的制备方法 - Google Patents
一种Avexitide的制备方法 Download PDFInfo
- Publication number
- CN112094336A CN112094336A CN202010635020.1A CN202010635020A CN112094336A CN 112094336 A CN112094336 A CN 112094336A CN 202010635020 A CN202010635020 A CN 202010635020A CN 112094336 A CN112094336 A CN 112094336A
- Authority
- CN
- China
- Prior art keywords
- resin
- avexitide
- avexide
- pro
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WSEVKKHALHSUMB-MVNVRWBSSA-N 133514-43-9 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=CC=C1 WSEVKKHALHSUMB-MVNVRWBSSA-N 0.000 title claims description 42
- 229940121528 avexitide Drugs 0.000 title claims description 42
- 238000002360 preparation method Methods 0.000 title description 12
- 229920005989 resin Polymers 0.000 claims abstract description 52
- 239000011347 resin Substances 0.000 claims abstract description 52
- 150000001413 amino acids Chemical class 0.000 claims abstract description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 22
- 239000000047 product Substances 0.000 claims abstract description 16
- 239000012043 crude product Substances 0.000 claims abstract description 14
- 229920003180 amino resin Polymers 0.000 claims abstract description 10
- 230000001681 protective effect Effects 0.000 claims abstract description 8
- 238000004108 freeze drying Methods 0.000 claims abstract description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 4
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 13
- JDDWRLPTKIOUOF-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-[[4-[2-[bis(4-methylphenyl)methylamino]-2-oxoethoxy]phenyl]-(2,4-dimethoxyphenyl)methyl]carbamate Chemical compound COC1=CC(OC)=CC=C1C(C=1C=CC(OCC(=O)NC(C=2C=CC(C)=CC=2)C=2C=CC(C)=CC=2)=CC=1)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JDDWRLPTKIOUOF-UHFFFAOYSA-N 0.000 claims description 8
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 3
- FZTIWOBQQYPTCJ-UHFFFAOYSA-N 4-[4-(4-carboxyphenyl)phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(O)=O)C=C1 FZTIWOBQQYPTCJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 238000011112 process operation Methods 0.000 abstract description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 22
- 239000012071 phase Substances 0.000 description 21
- 238000001914 filtration Methods 0.000 description 12
- 238000010828 elution Methods 0.000 description 11
- 238000000746 purification Methods 0.000 description 10
- 150000003839 salts Chemical group 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 7
- 238000011068 loading method Methods 0.000 description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 4
- ZPGDWQNBZYOZTI-UHFFFAOYSA-N 1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)C1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 2
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 1
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明提供了一种制备Avexitide的方法,方法中采用氨基树脂为起始树脂,按Avexitide的氨基序列反相依次接入相应的保护氨基酸得到Avexitide肽树脂,Avexitide保护肽树脂经酸解后获得Avexitide粗品,Avexitide粗品再经过纯化和冻干得到Avexitide纯品。本发明工艺操作简单,产品总收率高,适合规模化生产。
Description
技术领域
本发明属于多肽药物制备方法技术领域,特别涉及一种Avexitide的制备方法。
背景技术
Avexitide是一种GLP-1受体拮抗剂,这种多肽类药物包含31个氨基酸序列,可选择性地与GLP-1受体结合,阻断GLP-1的作用,从而防止胰岛素过度分泌,减少餐后低血糖的发生。Avexitide具有以下的结构:
Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Avexitide的制备方法已有很少有报道,本发明提供一种高效的Avexitide制备方法,以满足医药用途。
发明内容
本发明提供了一种高效的制备方法,采用氨基树脂为起始树脂,制备工艺操作简单,产品收率高、纯度高。
本发明提供了一种Avexitide的制备方法,包括:采用氨基树脂为起始树脂,按Avexitide的氨基序列反相依次接入相应的保护氨基酸得到Avexitide肽树脂,Avexitide保护肽树脂经酸解后获得Avexitide粗品,Avexitide粗品再经过纯化和冻干得到Avexitide纯品。
上述Avexitide的制备方法中,所述的氨基树脂的取代值为0.2~1.0mmol/g树脂,优选的取代值为0.3~0.6mmol/g树脂。
进一步的,所述氨基树脂选自Rink Amide-MBHA树脂、Rink Amide-BHA树脂和RinkAmide树脂,优选Rink Amide-MBHA树脂。
上述Avexitide的制备方法中,所述的Fmoc-保护氨基酸的用量为起始树脂氨基总摩尔数的1.2~6倍;优选为2.5~4.0倍。
作为本发明优选的方案,所述固相偶联合成法为:前一步反应得到的保护氨基酸-树脂脱去Fmoc保护基后再与下一个保护氨基酸偶联反应。所述的偶联反应时间为60~300分钟,优选的为100~140分钟。
Avexitide肽树脂为:
X-Asp(OtBu)-Leu-Ser(tBu)-Lys(Boc)-Gln(Trt)-Met-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ala-Val-Arg(Pbf)-Leu-Phe-Ile-Glu(OtBu)-Trp(Boc)-Leu-Lys(Boc)-Asn(Trt)-Gly-Gly-Pro-Ser(tBu)-Ser(tBu)-Gly-Ala-Pro-Pro-Pro-Ser(tBu)-氨基树脂
其中X为Boc,或为H
优选的,Avexitide肽树脂经酸解同时脱去树脂及侧链保护基得到Avexitide粗品:
进一步优选的,所述Avexitide肽树脂酸解时采用的酸解剂为三氟醋酸(TFA)、1,2-乙二硫醇(EDT)和水的混合溶剂;其中,混合溶剂的体积配比为:TFA为80~95%,EDT为1~10%,余量为水。
更进一步优选的,混合溶剂的体积配比为:TFA为89~91%、EDT为4~6%,余量为水。最优的,混合溶剂的体积配比为:TFA为90%、EDT为5%,余量为水。
所述酸解剂用量为每克Avexitide肽树脂需要4~15mL酸解剂;优选的,每克利Avexitide肽树脂需要9~11mL酸解剂。使用酸解剂裂解的时间为室温条件下1~6小时,优选的为3~4小时。
进一步的,Avexitide粗品经高效液相色谱纯化、冻干得到Avexitide纯品,具体方法为:
采用高效液相色谱法进行纯化,纯化用色谱填料为10μm的反相C18,采用两种流动相系统交替纯化,第一种流动相系统为0.1%TFA/水溶液-0.1%TFA/乙腈溶液,第二种流动相系统为50mmol醋酸铵/水溶液-乙腈,77mm*250mm的色谱柱流速为90mL/min,采用梯度系统洗脱,循环进样纯化,取粗品溶液上样于色谱柱中,启动流动相洗脱,收集主峰蒸去乙腈后,用0.45μm滤膜滤过,得Avexitide纯化中间体浓缩液;
采用高效液相色谱法进行换盐,流动相系统为1%醋酸/水溶液-乙腈,纯化用色谱填料为10μm的反相C18,77mm*250mm的色谱柱流速为90mL/min;采用梯度洗脱,循环上样方法,上样于色谱柱中,启动流动相洗脱,采集图谱,观测吸收度的变化,收集换盐主峰并用分析液相检测纯度,合并换盐主峰溶液,减压浓缩,得到Avexitide醋酸水溶液,冷冻干燥,得Avexitide纯品。
本发明工艺操作简单,产品总收率高,适合规模化生产。
具体实施方式
本发明公开了一种合成Avexitide的方法,本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。本发明的方法已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文所述方法进行改动或适当变更与组合,来实现和应用本发明技术。
在本发明具体实施方式中,申请文件中所用英文缩写对应的中文含义见下表。
下面结合实施例,进一步阐述本发明。
实施例1 Avexitide肽树脂的合成
Avexitide肽树脂为:
Boc-Asp(OtBu)-Leu-Ser(tBu)-Lys(Boc)-Gln(Trt)-Met-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ala-Val-Arg(Pbf)-Leu-Phe-Ile-Glu(OtBu)-Trp(Boc)-Leu-Lys(Boc)-Asn(Trt)-Gly-Gly-Pro-Ser(tBu)-Ser(tBu)-Gly-Ala-Pro-Pro-Pro-Ser(tBu)-Rink Amide-MBHA树脂
用Rink Amide-MBHA树脂为起始树脂,通过去Fmoc保护和偶联反应,依次与下表所示的保护氨基酸偶联,制得Avexitide肽树脂。本实施例使用的保护氨基酸相对应的保护氨基酸如表下所示:
接肽顺序n= | 保护氨基酸 |
1 | Fmoc-Ser(tBu) |
2 | Fmoc-Pro |
3 | Fmoc-Pro |
4 | Fmoc-Pro |
5 | Fmoc-Ala |
6 | Fmoc-Gly |
7 | Fmoc-Ser(tBu) |
8 | Fmoc-Ser(tBu) |
9 | Fmoc-Pro |
10 | Fmoc-Gly |
11 | Fmoc-Gly |
12 | Fmoc-Asn(Trt) |
13 | Fmoc-Lys(Boc) |
14 | Fmoc-Leu |
15 | Fmoc-Trp(Boc) |
16 | Fmoc-Glu(OtBu) |
17 | Fmoc-Ile |
18 | Fmoc-Phe |
19 | Fmoc-Leu |
20 | Fmoc-Arg(Pbf) |
21 | Fmoc-Val |
22 | Fmoc-Ala |
23 | Fmoc-Glu(OtBu) |
24 | Fmoc-Glu(OtBu) |
25 | Fmoc-Glu(OtBu) |
26 | Fmoc-Met |
27 | Fmoc-Gln(Trt) |
28 | Fmoc-Lys(Boc) |
29 | Fmoc-Ser(tBu) |
30 | Fmoc-Leu |
31 | Boc-Asp(OtBu) |
1、接入第2个保护氨基酸
取0.03mol第1个保护氨基酸和0.03mol HOBt,用适量DMF溶解;另取0.03mol DIC,搅拌下慢慢加入至保护氨基酸DMF溶液中,于室温环境中搅拌反应30分钟,得到活化后的保护氨基酸溶液,备用。
取0.01mol的Rink Amide-MBHA树脂(取代值约0.4mmol/g),采用20%PIP/DMF溶液去保护25分钟,洗涤过滤得到去Fmoc的树脂。
将活化后的第1个保护氨基酸溶液加入到已去Fmoc的树脂中,偶联反应120~300分钟,过滤洗涤,得含1个保护氨基酸的树脂。
2、接入第2~31个保护氨基酸
采用上述同样方法,依次接入上述对应的第2~31个保护氨基酸,得到Avexitide肽树脂。
实施例2 Avexitide肽树脂的合成
Avexitide肽树脂为:
H-Asp(OtBu)-Leu-Ser(tBu)-Lys(Boc)-Gln(Trt)-Met-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ala-Val-Arg(Pbf)-Leu-Phe-Ile-Glu(OtBu)-Trp(Boc)-Leu-Lys(Boc)-Asn(Trt)-Gly-Gly-Pro-Ser(tBu)-Ser(tBu)-Gly-Ala-Pro-Pro-Pro-Ser(tBu)-Rink Amide-MBHA树脂
用Rink Amide-MBHA树脂为起始树脂,通过去Fmoc保护和偶联反应,依次与下表所示的保护氨基酸偶联,制得Avexitide肽树脂。本实施例使用的保护氨基酸相对应的保护氨基酸如表下所示:
1、接入第1个保护氨基酸
取0.03mol第1个保护氨基酸和0.03mol HOBt,用适量DMF溶解;另取0.03mol DIC,搅拌下慢慢加入至保护氨基酸DMF溶液中,于室温环境中搅拌反应30分钟,得到活化后的保护氨基酸溶液,备用。
取0.01mol的Rink Amide-MBHA树脂(取代值约0.4mmol/g),采用20%PIP/DMF溶液去保护25分钟,洗涤过滤得到去Fmoc的树脂。
将活化后的第1个保护氨基酸溶液加入到已去Fmoc的树脂中,偶联反应120~300分钟,过滤洗涤,得含1个保护氨基酸的树脂。
2、接入第2~31个保护氨基酸
采用上述同样方法,依次接入上述对应的第2~31个保护氨基酸,得利Fmoc-保护的Avexitide肽树脂。
3、最后去保护
取Fmoc-保护的Avexitide肽树脂,采用20%PIP/DMF溶液去保护25分钟,洗涤过滤得到Avexitide肽树脂
实施例3 Avexitide粗品的制备
取实施例1制得的利Avexitide肽树脂,加入体积比为TFA︰水︰EDT=95︰5︰5的裂解试剂(裂解试剂10mL/克树脂),搅拌均匀,室温搅拌反应3小时,反应混合物使用砂芯漏斗过滤,收集滤液,树脂再用少量TFA洗涤3次,合并滤液后减压浓缩,加入无水乙醚沉淀,再用无水乙醚洗沉淀3次,35~45℃减压干燥,得Avexitide粗品。
实施例4 Avexitide粗品的制备
取实施例2制得的利Avexitide肽树脂,加入体积比为TFA︰水︰EDT=95︰5︰5的裂解试剂(裂解试剂10mL/克树脂),搅拌均匀,室温搅拌反应3小时,反应混合物使用砂芯漏斗过滤,收集滤液,树脂再用少量TFA洗涤3次,合并滤液后减压浓缩,加入无水乙醚沉淀,再用无水乙醚洗沉淀3次,35~45℃减压干燥,得Avexitide粗品。
实施例5 Avexitide粗品的纯化
取实施例3制得的Avexitide粗品,用10%醋酸溶液溶解,溶液用0.45μm混合微孔滤膜过滤,纯化备用;
采用高效液相色谱法进行纯化,纯化用色谱填料为10μm的反相C18,采用两种流动相系统交替纯化,第一种流动相系统为0.1%TFA/水溶液-0.1%TFA/乙腈溶液,第二种流动相系统为50mmol醋酸铵/水溶液-乙腈。77mm*250mm的色谱柱流速为90mL/min,采用梯度系统洗脱,循环进样纯化,取粗品溶液上样于色谱柱中,启动流动相洗脱,收集主峰蒸去乙腈后,用0.45μm滤膜滤过,得Avexitide纯化中间体浓缩液;
采用高效液相色谱法进行换盐,流动相系统为1%醋酸/水溶液-乙腈,纯化用色谱填料为10μm的反相C18,77mm*250mm的色谱柱流速为90mL/min;采用梯度洗脱,循环上样方法,上样于色谱柱中,启动流动相洗脱,采集图谱,观测吸收度的变化,收集换盐主峰并用分析液相检测纯度,合并换盐主峰溶液,减压浓缩,得到Avexitide醋酸水溶液,冷冻干燥,得Avexitide纯品8.5g,纯度为99.1%,最大单一杂质0.10%,总收率为25.2%,分子量为3369.8(100%M+H)。
实施例6 Avexitide粗品的纯化
取实施例4制得的Avexitide粗品,用10%醋酸溶液溶解,溶液用0.45μm混合微孔滤膜过滤,纯化备用;
采用高效液相色谱法进行纯化,纯化用色谱填料为10μm的反相C18,采用两种流动相系统交替纯化,第一种流动相系统为0.1%TFA/水溶液-0.1%TFA/乙腈溶液,第二种流动相系统为50mmol醋酸铵/水溶液-乙腈。77mm*250mm的色谱柱流速为90mL/min,采用梯度系统洗脱,循环进样纯化,取粗品溶液上样于色谱柱中,启动流动相洗脱,收集主峰蒸去乙腈后,用0.45μm滤膜滤过,得Avexitide纯化中间体浓缩液;
采用高效液相色谱法进行换盐,流动相系统为1%醋酸/水溶液-乙腈,纯化用色谱填料为10μm的反相C18,77mm*250mm的色谱柱流速为90mL/min;采用梯度洗脱,循环上样方法,上样于色谱柱中,启动流动相洗脱,采集图谱,观测吸收度的变化,收集换盐主峰并用分析液相检测纯度,合并换盐主峰溶液,减压浓缩,得到Avexitide醋酸水溶液,冷冻干燥,得Avexitide纯品8.9g,纯度为99.3%,最大单一杂质0.09%,总收率为26.4%,分子量为3369.6(100%M+H)。
上述实施例表明,本发明提供的方法所得产品纯度大于99.0%,产品总收率大于25%,具有广泛的实用价值和应用前景。
Claims (7)
1.一种Avexitide的制备方法,包括:采用氨基树脂为起始树脂,按Avexitide的氨基序列反相依次接入相应的保护氨基酸得到Avexitide肽树脂,Avexitide保护肽树脂经酸解后获得Avexitide粗品,Avexitide粗品再经过纯化和冻干得到Avexitide纯品:
Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-
Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-
Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH。2
2.根据权利要求1所述的Avexitide的制备方法,其特征在于:所述氨基树脂的取代值为0.2~1.0mmol/g树脂,优选的取代值为0.3~0.6mmol/g树脂。
3.根据权利要求2所述的氨基树脂选自Rink Amide-MBHA树脂、Rink Amide-BHA树脂和Rink Amide树脂,优选Rink Amide-MBHA树脂。
4.根据权利要求1所述的Avexitide的制备方法,其特征在于:所述的Avexitide肽树脂为:
X-Asp(OtBu)-Leu-Ser(tBu)-Lys(Boc)-Gln(Trt)-Met-Glu(OtBu)-
Glu(OtBu)-Glu(OtBu)-Ala-Val-Arg(Pbf)-Leu-Phe-Ile-Glu(OtBu)-
Trp(Boc)-Leu-Lys(Boc)-Asn(Trt)-Gly-Gly-Pro-Ser(tBu)-Ser(tBu)-
Gly-Ala-Pro-Pro-Pro-Ser(tBu)-氨基树脂
其中X为Boc,或为H。
5.根据权利要求1所述的Avexitide的制备方法,其特征在于:所述的Fmoc-保护氨基酸的用量为起始树脂氨基总摩尔数的1.2~6倍;优选为2.5~4.0倍。
6.根据权利要求1~5任一项所述的Avexitide的制备方法,其特征在于:Avexitide肽树脂经酸解同时脱去树脂及侧链保护基得到Avexitide粗品。
7.根据权利要求1所述的Avexitide的制备方法,其特征在于:Avexitide粗品经高效液相色谱纯化、冻干得到Avexitide纯品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010635020.1A CN112094336A (zh) | 2020-07-03 | 2020-07-03 | 一种Avexitide的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010635020.1A CN112094336A (zh) | 2020-07-03 | 2020-07-03 | 一种Avexitide的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112094336A true CN112094336A (zh) | 2020-12-18 |
Family
ID=73750671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010635020.1A Pending CN112094336A (zh) | 2020-07-03 | 2020-07-03 | 一种Avexitide的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112094336A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005100388A1 (en) * | 2004-04-19 | 2005-10-27 | Biocon Limited | Production of insulinotropic peptides |
CN101280009A (zh) * | 2005-06-29 | 2008-10-08 | 常州制药厂有限公司 | Exendin 4多肽片段 |
CN102584944A (zh) * | 2012-02-06 | 2012-07-18 | 成都圣诺科技发展有限公司 | 一种依非巴特的制备方法 |
CN104854126A (zh) * | 2012-11-30 | 2015-08-19 | 国立大学法人京都大学 | 多肽及成像方法 |
-
2020
- 2020-07-03 CN CN202010635020.1A patent/CN112094336A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005100388A1 (en) * | 2004-04-19 | 2005-10-27 | Biocon Limited | Production of insulinotropic peptides |
CN101280009A (zh) * | 2005-06-29 | 2008-10-08 | 常州制药厂有限公司 | Exendin 4多肽片段 |
CN102584944A (zh) * | 2012-02-06 | 2012-07-18 | 成都圣诺科技发展有限公司 | 一种依非巴特的制备方法 |
CN104854126A (zh) * | 2012-11-30 | 2015-08-19 | 国立大学法人京都大学 | 多肽及成像方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110903355A (zh) | 一种Tirzepatide的制备方法 | |
CN107960079B (zh) | 一种低消旋杂质利拉鲁肽的合成方法 | |
CN107056927B (zh) | 一种利拉鲁肽的制备方法 | |
CN101357936B (zh) | 固相多肽合成曲普瑞林的制备方法 | |
US20140187745A1 (en) | Method for preparing bivalirudin | |
CN106699871A (zh) | 一种利拉鲁肽的制备方法 | |
CN103333239B (zh) | 固相合成胰高血糖素 | |
CN102408471A (zh) | 特利加压素的制备方法 | |
CN110818790A (zh) | 一种替莫瑞林的制备方法 | |
US9394341B2 (en) | Eptifibatide preparation method | |
CN110922470A (zh) | 一种索玛鲁肽的制备方法 | |
CN101357937B (zh) | 固相多肽合成阿托西般的制备方法 | |
CN104817638B (zh) | 一种合成替度鲁肽的方法 | |
CN110054662B (zh) | 一种固相合成Etelcalcetide的方法 | |
CN110759972A (zh) | 一种阿托西班的制备方法 | |
CN106632655B (zh) | 一种艾塞那肽的制备方法及其产品 | |
CN1865283B (zh) | 固相多肽合成鲑鱼降钙素的制备方法 | |
CN106243214B (zh) | 一种美拉诺坦ⅰ的制备方法 | |
CN111217901A (zh) | 一种索马鲁肽的制备方法 | |
CN107778351B (zh) | 一种全固相合成奥曲肽的方法 | |
CN111718408A (zh) | 一种Setmelanotide的制备方法 | |
CN112094336A (zh) | 一种Avexitide的制备方法 | |
CN105111301B (zh) | 一种鲑鱼降钙素的制备方法 | |
CN111560061A (zh) | 一种Gelpaglutide的制备方法 | |
CN111518192A (zh) | 一种Apraglutide的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201218 |